The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030<RootsAnalysis>

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this –

Key Inclusions
 A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thrice daily and others) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, the chapter includes information on drug developer(s), including information on year of establishment, company size, and location of headquarters.
 Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs. Each profile features a brief overview of the company, its financial information (if available), product portfolio and an informed future outlook.
 An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations.
 An analysis of the partnerships that have been established in the recent past, covering acquisitions.

Gaurav Chaudhary
+1 (415) 800 3415

+44 (122) 391 1091

Leave a Reply

Your email address will not be published. Required fields are marked *